Influenza A/B + SARS-CoV-2 Ag Combo Rapid Test Device

Influenza A, Influenza B, and SARS-CoV-2 are respiratory viruses that can produce similar symptoms such as fever, cough, sore throat, body aches, headache, fatigue, and respiratory discomfort. Combo testing helps healthcare professionals screen for multiple respiratory pathogens using a single specimen collection workflow.

• Rapid respiratory infection testing supports early clinical decision-making and infection-control planning.
• Influenza and COVID-19 symptoms may overlap, making differential screening important during seasonal outbreaks.
• Combo testing can support workflow efficiency by screening for multiple pathogens in one test format.
• Rapid detection may help guide isolation recommendations, patient triage, and follow-up testing strategies.

The Influenza A/B + SARS-CoV-2 Ag Combo Rapid Test Device by LARKSOIS Pharma may be used in professional respiratory infection screening environments.

Applications

• Hospitals and clinics
• Emergency departments
• Diagnostic laboratories
• Fever clinics
• Respiratory infection screening programs
• Public health outbreak response programs
• Travel and workplace health screening
• Professional point-of-care testing
• International diagnostic distribution

• The Influenza A/B + SARS-CoV-2 Ag Combo Rapid Test Device works on lateral flow immunochromatographic assay technology.
• After specimen collection, the nasal or nasopharyngeal swab is mixed with extraction buffer.
• The prepared sample is applied to the test cassette.
• If Influenza A antigen, Influenza B antigen, or SARS-CoV-2 antigen is present, the corresponding test line becomes visible.
• The control line confirms valid sample migration and proper test performance.

The Influenza A/B + SARS-CoV-2 Ag Combo Rapid Test Device uses rapid lateral flow immunochromatographic technology for qualitative detection of Influenza A antigen, Influenza B antigen, and SARS-CoV-2 antigen in nasal or nasopharyngeal swab specimens.

Benefits

• Detects Influenza A antigen
• Detects Influenza B antigen
• Detects SARS-CoV-2 antigen
• Rapid visual result
• Uses nasal or nasopharyngeal swab specimens
• No complex instrument required
• Supports respiratory outbreak screening
• Professional point-of-care diagnostic application

The combo rapid test device supports nasal swab and nasopharyngeal swab specimens. Correct specimen collection is important because test performance depends on sample quality, viral load, timing after symptom onset, and correct procedure.

Guidance

• Use approved nasal or nasopharyngeal swab specimens only
• Collect specimens according to the product insert
• Use clean and suitable swab collection materials
• Avoid contaminated or improperly collected samples
• Mix the swab specimen with extraction buffer correctly
• Apply the prepared sample properly to the test cassette
• Read results only within the recommended time window
• Handle respiratory specimens according to laboratory safety procedures

Note

Specimen collection, extraction, testing, timing, and storage should always follow the official LARKSOIS Pharma kit insert.

The Influenza A/B + SARS-CoV-2 Ag Combo Rapid Test Device by LARKSOIS Pharma is designed for qualitative detection of Influenza A antigen, Influenza B antigen, and SARS-CoV-2 antigen in respiratory swab specimens. Results should be interpreted with symptoms, clinical evaluation, and local respiratory infection activity.

• A positive result means one or more target antigens have been detected.
• Rapid combo screening may support timely patient management and infection-control measures.
• A negative result does not completely rule out respiratory infection.
• If symptoms continue or clinical suspicion remains high, molecular testing such as PCR may still be recommended.

Rapid antigen combo tests provide fast screening support, but molecular methods are generally more sensitive. The Influenza A/B + SARS-CoV-2 Ag Combo Rapid Test Device should be used as a professional screening aid and not as the only basis for diagnosis or treatment decisions.

Instructions

• For professional in-vitro diagnostic use only
• Use approved respiratory specimens only
• Improper specimen collection may affect results
• False negative or false positive results may occur
• Negative results may require confirmation when symptoms strongly suggest infection
• PCR testing may be recommended when clinical suspicion remains high
• Read results only within the recommended time
• Follow the official product insert carefully

Instructions

• Detects Influenza A antigen
• Detects Influenza B antigen
• Detects SARS-CoV-2 antigen
• Rapid visual result
• Uses nasal or nasopharyngeal swab specimens
• No complex instrument required
• Supports respiratory outbreak screening
• International-quality diagnostic product from LARKSOIS Pharma

Note

The Influenza A/B + SARS-CoV-2 Ag Combo Rapid Test Device by LARKSOIS Pharma is designed for practical use, rapid screening, and professional healthcare supply requirements.

Steps

• Bring the test device, specimen, and extraction buffer to room temperature
• Collect the nasal or nasopharyngeal swab specimen according to instructions
• Place the swab into the extraction buffer tube
• Mix the sample properly as instructed in the product insert
• Remove the test cassette from the sealed pouch
• Apply the prepared specimen to the sample well
• Wait for the recommended reaction time
• Read the test and control lines within the valid time window
• Dispose of used materials according to laboratory safety procedures

Note

Testing should be performed by trained healthcare professionals according to the official LARKSOIS Pharma product insert.

Positive

A positive result means Influenza A antigen, Influenza B antigen, and/or SARS-CoV-2 antigen has been detected. Results should be interpreted with symptoms, exposure history, and local outbreak activity.

Negative

A negative result means target antigens were not detected at the test’s detectable level. If symptoms continue or clinical suspicion remains high, molecular testing such as PCR may still be recommended.

Invalid

If the control line does not appear, the test result is invalid. Repeat testing with a fresh test device is required.

Instructions

• Store the combo rapid test device according to the product label and insert
• Store in a cool and dry place
• Keep sealed until use
• Protect from heat, sunlight, and moisture
• Do not freeze unless specified
• Do not use expired kits
• Use immediately after opening the pouch
• Follow all instructions for use carefully

Instructions

• For professional in-vitro diagnostic use only
• Handle respiratory specimens carefully
• Wear gloves and appropriate protective equipment during testing
• Do not reuse the test cassette
• Avoid specimen contamination
• Do not use damaged or expired kits
• Read results only within the recommended time
• Interpret results with clinical findings and local outbreak activity

LARKSOIS Pharma provides globally suitable diagnostic products for hospitals, laboratories, clinics, healthcare procurement agencies, and medical distributors. The Influenza A/B + SARS-CoV-2 Ag Combo Rapid Test Device is designed for fast, accessible, and practical respiratory infection screening.

Advantages

• International infectious disease rapid test portfolio
• Reliable respiratory infection screening support
• Suitable for hospitals, clinics, and laboratories
• Distributor-friendly product support
• Professional healthcare quality standards
• Practical point-of-care diagnostic format
• Accessible combo respiratory screening solution